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CASE REPORT
Treatment of total exudative retinal detachment 
due to central retinal vein occlusion by intravitreal 
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Objective: To report on the use of intravitreal bevacizumab (an anti-vascular endothelial growth 
factor [VEGF] monoclonal antibody) as treatment of diffuse exudative retinal detachment due 
to ischemic central retinal vein occlusion (CRVO).
Design: Interventional case report.
Patient: A 27-year old woman on peritoneal dialysis because of end stage renal failure (ESRF) 
due to perinuclear antineutrophil cytoplasmic antibody (p-ANCA) associated vasculitis presented 
with acute unilateral blurred vision. Visual acuity (VA) rapidly deteriorated. Examination 
revealed the development of total bullous exudative retinal detachment following ischemic 
CRVO.
Intervention: Two intravitreal injections of bevacizumab (2.5 mg/0.1ml) were administered 
followed by panretinal laser photocoagulation.
Main outcome measures: VA, retinal detachment, and changes in macular edema.
Results: Prompt signiﬁ  cant resolution of exudative retinal detachment with a corresponding 
gradual improvement of VA from light perception to ﬁ  nger counting. At follow-up examination 
after 8-months, the retina remained attached.
Conclusion: Intravitreal bevacizumab proved to be a useful treatment modality in diffuse 
exudative retinal detachment due to CRVO.
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Introduction
Exudative retinal detachment is an uncommon complication of retinal vein occlusion 
(Schatz et al 1976; Battaglia Parody and Isola 1994). Bullous retinal detachment may 
respond to panretinal laser photocoagulation (PRP) (Schatz et al 1976; Battaglia Parody 
and Isola 1994) or to intravitreal triamcinolone acetonide injection (Karacorlu et al 
2005). This report describes a young woman with end stage renal failure (ESRF) due 
to perinuclear antineutrophil cytoplasmic antibody (p-ANCA) associated vasculitis 
who developed central retinal vein occlusion (CRVO) and very high bullous exudative 
retinal detachment. She was successfully treated with two intravitreal bevacizumab 
(AvastinR, Genentech, Inc., San Francisco, CA) injections. To the best of our knowl-
edge, this has not been previously reported.
Case report
A 27-year old woman presented with a 3 day history of blurred vision in her right 
eye. Six months prior she was admitted with malignant hypertension (blood pressure 
of 240/140 mmHg and disc edema) and renal failure. Based on a positive p-ANCA 
with antimyeloperoxidase antibodies (MPO) 84 U/ml (normal  5 U/ml) and renal 
biopsy, she was diagnosed as ESRF due to p-ANCA associated vasculitis. Peritoneal Clinical Ophthalmology 2007:1(3) 348
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dialysis was begun. Treatment with high-dose steroids and 
azathioprine was initiated. Blood pressure was controlled 
by multiple antihypertensive drugs. The patient’s disc 
edema gradually resolved. Over the course of the follow-
ing six months, basal disease activity subsided. She was 
well maintained on dialysis with serum hemoglobin of 
11.2 g/dl, hematocrit 33.4%, total protein 6.9 g/dl, and 
albumin 3.8 g/dl.
On presentation, visual acuity (VA) was 6/30 (20/100) 
in her right eye and 6/8.5 (20/30) in her left eye. Anterior 
segments in both eyes were normal. Funduscopic ﬁ  ndings 
revealed clinical characteristics of CRVO in the right eye and 
no abnormality in her left eye. A coagulation screen including 
activated protein C resistance, protein S, antiphospholipid 
antibodies, and homocystein was within normal limits. MPO 
levels were 6.8 U/ml on maintenance oral prednisone (5 mg/d) 
and azathioprine (50 mg/d). Fluorescein angiography (FA) 
performed after 3-days showed a nonischemic CRVO with 
mild macular edema.
Three weeks later the patient noticed further visual dete-
rioration in her right eye. Examination revealed VA 6/120 
(20/400), reduced color vision, mild positive relative afferent 
pupillary defect (RAPD), and an exacerbation of macular 
edema. Oral prednisone was increased to 20 mg per day. 
During the ensuing month, VA in the right eye declined to 
hand motion and RAPD became signiﬁ  cantly positive. Severe 
optic disc and macular edema were seen and FA demon-
strated severe ischemic CRVO with diffuse retinal leakage. 
At ﬁ  fty days after ﬁ  rst complaining of blurred vision, the 
patient’s VA had dropped to light perception only. A total 
very high bullous exudative retinal detachment was found 
without evidence of retinal break. The left eye’s VA, anterior 
segment, media, and retina were unaffected. Suspecting a 
relapse of her vasculitis (although MPO levels remained 
Figure 1 Two months after intravitreal bevacizumab injection; showing attached retina, retinal hemorrhages, and multiple cotton wool spots.Clinical Ophthalmology 2007:1(3) 349
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unchanged) a treatment trial of high-dose prednisone 
(60 mg/d) with an increase of azathioprine (100 mg/d) was 
attempted. After 2-days, no improvement was seen. As the 
patient was very reluctant to continue high-dose steroids due 
to previous severe cushingoid side effects, steroid therapy 
was rapidly tapered.
After discussing treatment options with the patient and 
explaining to her the potential risks and beneﬁ  ts of bevaci-
zumab, the patient signed a comprehensive informed consent 
form. On obtaining approval from the Ethics Committee of 
Meir Medical Center, she underwent a pars plana injection 
of 2.5 mg of bevacizumab. The injection was well tolerated 
without any untoward side effects. Topical antibiotic treat-
ment was given for one week after the injection. Twenty-four 
hours after bevacizumab administration, a marked reduction 
in the amount of the subretinal ﬂ  uid was seen. VA improved 
to counting ﬁ  ngers after two days. A week following injection 
only a residual inferior exudative retinal detachment remained 
and a continuous improvement in macular edema and optic 
disc swelling was seen. At the two months follow-up exami-
nation the macular and disc edema resolved completely and 
no exudative retinal detachment was noted in any part of the 
retina (Figures 1, 2). VA, however, did not improve beyond 
ﬁ  nger counting probably due to the severe perifoveal capillary 
drop out (Figure 3). At the 3-months follow up examination a 
recurrent bullous subtotal exudative retinal detachment was 
found. An additional 2.5 mg of bevacizumab was injected into 
the vitreous cavity and one week later the retinal detachment 
reabsorbed completely. At this point panretinal laser photo-
coagulation was performed. At the last follow up (8-months), 
the retina has remained attached.
Discussion
CRVO is a relatively common disorder affecting mainly 
adults over 50-years of age (Clarkson 1989). The most com-
mon risk factors are arterial hypertension and primary open 
angle glaucoma (Clarkson 1989). CRVO associated with 
systemic vasculitis has been described in the context of syphi-
lis (Primo 1990) and human immunodeﬁ  ciency syndrome 
(HIV) (Roberts and Haefs 1992). Its occurrence, however, in 
the younger adult is rare. In this report, we present a young 
woman with ESRF due to p-ANCA vasculitis who developed 
a nonischemic CRVO which rapidly progressed to a severe 
ischemic CRVO. p-ANCA vasculitis as an etiology of CRVO 
is decidedly uncommon. A literature search has yielded only 
one other such case (Ishiguro et al 1999). The progression 
of nonischemic to ischemic CRVO with the development of 
an exudative retinal detachment is very infrequently seen in 
young patients. In our patient, CRVO occurred in the absence 
of any coagulation abnormality and in the presence of well 
controlled hypertension. Although no increase in antimyelo-
peroxidase antibody levels was documented at the time the 
CRVO appeared, it can be conjectured that the CRVO was 
probably caused by a localized vasculitis.
The appearance of total exudative retinal detachment 
in our patient is a unique feature. Previous descriptions of 
cases having exudative retinal detachment as a complication 
of retinal venous occlusive disease were all characterized by 
partial retinal detachment (Schatz et al 1976; Battaglia Parody 
and Isola 1994; Karacorlu et al 2005). This usually allowed 
treatment with laser photocoagulation with resultant reabsorp-
tion of the subretinal ﬂ  uid. In our case, the detachment was 
highly bullous, involving the entire retina, a ﬁ  nding which 
Figure 2 OCT 2 months after intravitreal bevacizumab injection showing no residual subretinal or intraretinal ﬂ  uid in the macular area.
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precluded laser treatment. It began by an ischemic CRVO 
with diffuse capillary drop out at the entire retina including 
the macula, progressed to severe disc and macular edema and, 
within a week, a total bullous retinal detachment.
Rather than triamcinolone, we chose to treat our patient 
with intravitreal bevacizumab due to the relative failure of 
high-dose systemic steroids and fear of cataract formation 
in a young patient.
The pathogenesis of bullous retinal detachment remains 
speculative. Schatz et al (1976) suggested that in severe 
capillary nonperfusion the ischemic retina provides a toxic 
stimulus to the patent retinal vessels causing capillary 
leakage. The severe venous obstruction and the lack of 
compensating veno-venous collaterals lead to a large volume 
of extra cellular ﬂ  uid which exceeds the retina’s reabsorp-
tive capacity and an exudative retinal detachment develops. 
Implicated etiological factors have included increased venous 
hydrostatic pressure and an impairment of the pumping 
activity of the retinal pigment epithelium (RPE) (Battaglia 
Parody and Isola 1994).
We suggest that VEGF plays a main role in the devel-
opment of exudative retinal detachment in CRVO. VEGF 
acts through a variety of pathways, many of which promote 
pathological neovascularization. In addition, VEGF is a 
powerful agonist of vascular permeability. Increased vascular 
permeability in response to VEGF may be due to formation 
of fenestrations in microvascular endothelium (Roberts and 
Palade 1995). In severe retinal ischemia certain growth fac-
tors including VEGF are probably discharged into the vitre-
ous. This will lead to extensive exudation from the retinal 
vessels including the vessels of the optic disc (the disc was 
very edematous prior to the detachment) exceeding the 
reabsorptive capability of the RPE pump. Counteracting 
the effects of VEGF by bevacizumab probably decreases 
Figure 3 Fluorescein angiography 2 months after intravitreal bevacizumab injection (mid phase) showing drop out of retinal capillaries throughout the entire posterior pole.Clinical Ophthalmology 2007:1(3) 351
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the exudative volume thereby allowing the absorption of 
the subretinal ﬂ  uid by the RPE pump. We postulate that the 
beneﬁ  cial effect of laser treatment is due to its reduction of 
VEGF upon ablation of large parts of the ischemic retina. In 
contrast to what is currently thought, the pumping activity 
of the RPE is probably intact. We, therefore, imply that 
even in partial exudative detachment due to CRVO, prompt 
intravitreal injection of bevacizumab followed by laser PRP 
may act much better than the current accepted modality of 
laser photocoagulation alone.
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